Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
OHE Launches Discussion Paper and Consultation Exercise on Indication-based Pricing
10 May 2019
Increasingly, scientific advances are delivering new medicines that deliver improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as…
OHE at ISPOR 2019
8 May 2019
Meet some of the OHE team at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019 conference in New Orleans, 18-22 May.
Is Rate Of Return Pricing A Useful Approach When Value-Based Pricing Is Not Appropriate?
22 March 2019
Value-based pricing (VBP) is an efficient method for pricing new drugs. Rate of return pricing could, however, be useful in two cases: treatments for ultra-rare diseases,…
Abolishing Pharmaceutical Rebates in the US? Looking at the Trade-Offs
12 March 2019
The combination of rising drug costs in the US and increasing financial stress for individual patients has triggered intense national concern. One target has come under…
The World Needs Better Drugs for TB. The Center for Global Development and OHE Have a Proposal and We Need your Feedback
5 March 2019
Innovation is a critical tool in the global fight against tuberculosis (TB), an infectious disease that primarily affects the poor and vulnerable and ranks among the…
Data Governance Arrangements for Real-World Evidence in Japan
1 September 2019
In 2015, OHE Consulting published a report on data governance arrangements for real-world evidence (RWE) covering the specifics under which RWE was used in eight different…
The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
1 July 2019
The present work aims to assess the life-cycle value of innovative medicines based on the example of Second-Generation Antipsychotics (SGA). Assessing the entire life-cycle of SGA,…
Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?
1 June 2019
Cada vez más, los avances científicos desarrollan nuevas medicinas que permiten mejoras en la supervivencia y calidad de vida para diversas indicaciones terapéuticas. La fijación de…
Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?
1 May 2019
Increasingly, scientific advances are delivering new medicines that deliver improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as…